Sugi Predict

Sugi Predict / Targets / HDAC2

HDAC2

Histone deacetylase 2 · Q92769 · HDAC2 on Sugi Atlas →

643,489 patent compounds predicted against HDAC2, 398,784 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vorinostat Vorinostat (SCHEMBL9018) 1.00 14/20
SCHEMBL28250 SCHEMBL28250 0.57 14/20
SCHEMBL29476 SCHEMBL29476 0.57 14/20
SCHEMBL31064 SCHEMBL31064 0.57 14/20
SCHEMBL30259 SCHEMBL30259 0.57 14/20
SCHEMBL28328 SCHEMBL28328 0.61 13/20
SCHEMBL28329 SCHEMBL28329 0.61 13/20
SCHEMBL28330 SCHEMBL28330 0.61 13/20
SCHEMBL29695 SCHEMBL29695 0.61 13/20
SCHEMBL30199 SCHEMBL30199 0.61 13/20
SCHEMBL21138 SCHEMBL21138 0.55 12/20
SCHEMBL21139 SCHEMBL21139 0.55 12/20
SCHEMBL21140 SCHEMBL21140 0.55 12/20
SCHEMBL30622 SCHEMBL30622 0.55 12/20
SCHEMBL34229 SCHEMBL34229 0.51 12/20
SCHEMBL19539 SCHEMBL19539 0.48 11/20
Trichostatin Trichostatin (SCHEMBL19886) 1.00 10/20
SCHEMBL28840 SCHEMBL28840 0.61 9/20
SCHEMBL28841 SCHEMBL28841 0.61 9/20
SCHEMBL28842 SCHEMBL28842 0.61 9/20

Clinical trials — most relevant to HDAC2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer PHASE2COMPLETED
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. PHASE2COMPLETED
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE2COMPLETED
Clinical Trial of SAHA in Patients With Breast Cancer PHASE1/PHASE2UNKNOWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma PHASE1COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Imaging Histone Deacetylase in the Heart nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HDAC2 binder may also engage these)

ProteinNameSimilarity
P56519 — 1.000 P56519 →
Q5RAG0 — 1.000 Q5RAG0 →
Q32PJ8 — 1.000 Q32PJ8 →
P70288 — 1.000 P70288 →
O09106 — 1.000 O09106 →
P56517 — 1.000 P56517 →
Q4QQW4 — 0.997 Q4QQW4 →
Q91695 — 0.997 Q91695 →
O42227 — 0.997 O42227 →
HDAC1 Histone deacetylase 1 0.997 landscape →
Q94517 — 0.994 Q94517 →
P56518 — 0.994 P56518 →
Q7Y0Y8 — 0.993 Q7Y0Y8 →
O13298 — 0.993 O13298 →
Q7Y0Y6 — 0.992 Q7Y0Y6 →
Q9FML2 — 0.991 Q9FML2 →
Q8H0W2 — 0.991 Q8H0W2 →
O22446 — 0.990 O22446 →
Q6YV04 — 0.990 Q6YV04 →
Q803C3 — 0.990 Q803C3 →
P32561 — 0.990 P32561 →
Q09440 — 0.989 Q09440 →
Q55BW2 — 0.989 Q55BW2 →
O17695 — 0.988 O17695 →
O59702 — 0.988 O59702 →
Q55FN5 — 0.988 Q55FN5 →
Q6IRL9 — 0.988 Q6IRL9 →
Q4SFA0 — 0.987 Q4SFA0 →
Q9FH09 — 0.987 Q9FH09 →
P56521 — 0.987 P56521 →